Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026)
Soleno Therapeutics (SLNO) reported Income from Continuing Operations of 31378000.0 for Q1 2026, up 171.68% year-over-year from 11549470.2 in Q1 2025, and down 27.63% on a QoQ basis from 43358000.0 in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Income from Continuing Operations data on file, last reported at 31378000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 171.68% year-over-year to 31378000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96041000.0 (up 148.51% YoY) and the FY2025 annual result came in at 20890000.0, up 111.88% from the prior year.
- Income from Continuing Operations declined to 31378000.0 in Q1 2026 per SLNO's latest filing, from 43358000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 43358000.0 in Q4 2025 and bottomed at 76616000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 8356000.0 (2023), against an average of 10973764.71.
- The widest annual swing landed in 2024, when Income from Continuing Operations tumbled 650.55%; it then jumped 177.77% in 2025.
- Tracing SLNO's Income from Continuing Operations over 5 years: stood at 5610000.0 in 2022, then sank by 109.73% to 11766000.0 in 2023, then tumbled by 373.83% to 55751000.0 in 2024, then jumped by 177.77% to 43358000.0 in 2025, then slipped by 27.63% to 31378000.0 in 2026.
- Per Business Quant, the three latest SLNO Income from Continuing Operations figures stand at 31378000.0 (Q1 2026), 43358000.0 (Q4 2025), and 26013000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.36 Mn |
| Sep 30, 2025 | 26.01 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.75 Mn |
| Sep 30, 2024 | -76.62 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -21.40 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | -10.21 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -6.24 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -5.77 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.29 Mn |
| Jun 30, 2021 | -11.09 Mn |
| Mar 31, 2021 | -9.16 Mn |
| Dec 31, 2020 | -7.96 Mn |
| Sep 30, 2020 | -7.86 Mn |
| Jun 30, 2020 | -11.19 Mn |
| Mar 31, 2020 | -9.28 Mn |
| Dec 31, 2019 | -6.75 Mn |
| Sep 30, 2019 | -6.13 Mn |
| Jun 30, 2019 | -5.62 Mn |
| Mar 31, 2019 | -4.98 Mn |
| Dec 31, 2018 | -3.54 Mn |
| Sep 30, 2018 | -3.88 Mn |
| Jun 30, 2018 | -3.41 Mn |
| Mar 31, 2018 | -3.48 Mn |
| Dec 31, 2017 | -5.20 Mn |
| Sep 30, 2017 | -2.63 Mn |
| Jun 30, 2017 | -2.97 Mn |
| Mar 31, 2017 | -1.37 Mn |
| Dec 31, 2016 | -1.83 Mn |
| Sep 30, 2016 | -1.97 Mn |
| Jun 30, 2016 | -2.30 Mn |
| Mar 31, 2016 | -4.26 Mn |
| Dec 31, 2015 | -3.51 Mn |
| Sep 30, 2015 | -3.18 Mn |
| Jun 30, 2015 | -3.04 Mn |
| Mar 31, 2015 | -2.43 Mn |
| Dec 31, 2014 | -4.17 Mn |
| Sep 30, 2014 | -2.08 Mn |
| Jun 30, 2014 | -1.98 Mn |
| Mar 31, 2014 | -1.07 Mn |
| Dec 31, 2013 | -869,278.00 |
| Sep 30, 2013 | -1.56 Mn |